VIRGINIA RETIREMENT SYSTEMS ET Al Purchases New Shares in AxoGen, Inc. $AXGN

VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in AxoGen, Inc. (NASDAQ:AXGN) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 10,900 shares of the medical equipment provider’s stock, valued at approximately $118,000.

Several other institutional investors have also added to or reduced their stakes in the company. Primoris Wealth Advisors LLC boosted its stake in AxoGen by 9.0% in the 2nd quarter. Primoris Wealth Advisors LLC now owns 15,700 shares of the medical equipment provider’s stock valued at $170,000 after purchasing an additional 1,300 shares during the period. HighMark Wealth Management LLC boosted its stake in AxoGen by 174.5% in the 2nd quarter. HighMark Wealth Management LLC now owns 98,085 shares of the medical equipment provider’s stock valued at $1,064,000 after purchasing an additional 62,350 shares during the period. Assenagon Asset Management S.A. raised its holdings in AxoGen by 2.2% in the 2nd quarter. Assenagon Asset Management S.A. now owns 1,023,122 shares of the medical equipment provider’s stock valued at $11,101,000 after acquiring an additional 21,905 shares in the last quarter. Exchange Traded Concepts LLC raised its holdings in AxoGen by 50.9% in the 2nd quarter. Exchange Traded Concepts LLC now owns 77,312 shares of the medical equipment provider’s stock valued at $839,000 after acquiring an additional 26,077 shares in the last quarter. Finally, Rhumbline Advisers lifted its position in shares of AxoGen by 3.5% during the 1st quarter. Rhumbline Advisers now owns 60,264 shares of the medical equipment provider’s stock valued at $1,115,000 after acquiring an additional 2,032 shares during the period. 80.29% of the stock is currently owned by institutional investors.

AxoGen Price Performance

AxoGen stock opened at $18.17 on Monday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 2.67 and a current ratio of 4.14. AxoGen, Inc. has a 52 week low of $9.22 and a 52 week high of $21.00. The stock has a market capitalization of $836.00 million, a P/E ratio of -181.68 and a beta of 1.04. The stock has a fifty day moving average of $16.63 and a 200-day moving average of $14.05.

Insider Activity at AxoGen

In other news, Director William P. Mr. Burke sold 14,571 shares of the business’s stock in a transaction on Friday, October 3rd. The stock was sold at an average price of $18.21, for a total transaction of $265,337.91. Following the completion of the transaction, the director owned 2,293 shares of the company’s stock, valued at approximately $41,755.53. The trade was a 86.40% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Over the last ninety days, insiders sold 35,521 shares of company stock worth $642,219. 2.78% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on AXGN shares. Wall Street Zen upgraded AxoGen from a “hold” rating to a “buy” rating in a research report on Saturday, August 9th. HC Wainwright started coverage on AxoGen in a research report on Tuesday, September 30th. They set a “buy” rating and a $25.00 target price for the company. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of AxoGen in a research report on Friday. Four research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $25.75.

AxoGen Profile

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.